Immunodiagnostic Systems Hldgs PLC Launch of SARS-CoV-2 Antigen Rapid Tests (6864G)

TIDMIDH

RNS Number : 6864G

Immunodiagnostic Systems Hldgs PLC

27 November 2020

Immunodiagnostic Systems Holdings plc.

27 November 2020

Launch of SARS-CoV-2 Antigen Rapid Tests

Immunodiagnostic Systems Holdings plc (IDS), a specialty solution provider to the clinical laboratory diagnostic market, announces that two SARS-CoV-2 Antigen Rapid Test kits are now available for sale in the UK, European Union and other countries which accept the CE mark as the basis of regulatory approval.

Both tests can be performed by a trained healthcare professional in community locations (e.g. workplaces, schools, doctors' surgeries) without the need for any laboratory equipment. These tests determine the presence of the SARS-CoV-2 nucleocapsid protein antigen using direct nasopharyngeal swab samples, providing a result within 15 minutes.

Both fast and easy to use tests are based on the lateral flow principle: one in a cassette format, one in a test card format. These tests are provided by partners of IDS, and have been assessed by the manufacturers as having the following performance characteristics:

 
                 Specificity   Sensitivity   Time to Result 
 Lateral Flow 
  cassette          99.2%         96.7%        15 minutes 
                ------------  ------------  --------------- 
 Lateral Flow 
  card              99.3%         92.0%        15 minutes 
                ------------  ------------  --------------- 
 

IDS now offers a comprehensive portfolio of SARS-CoV-2 antigen and antibody tests for the laboratory as well as for community locations; additional information of our SARS-CoV-2 assay portfolio can be found on the IDS website at www.idsplc.com .

For further information:

   Immunodiagnostic Systems Holdings plc                             Tel: [phone] 

Jaap Stuut, Chief Executive Officer

Paul Martin, Group Finance Director

Peel Hunt LLP Tel: [phone]

James Steel

Oliver Jackson

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

PRLBFBRTMTMTBFM

(END) Dow Jones Newswires

November 27, 2020 02:00 ET (07:00 GMT)